Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00493467
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibritumomab Tiuxetan (Zevalin) — DRUG
    111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1. 90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.
  • Rituximab — DRUG
    250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.

Study Details

The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.

Key Dates

Start date
Jun 30, 2006
Status verified
Aug 2022
Primary completion
Apr 30, 2015
Completion
Aug 11, 2022

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zevalin
    Ibritumomab Tiuxetan (Zevalin) + Rituximab

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to 5 years; Evaluation at 3-month intervals during Year 1, then every 6 months to Year 4. The median follow-up was 56 months for censored observations. ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies